Fig. 1

Flow chart of patient selection. Medical records of patients who underwent RALP between July 1, 2012 and July 31, 2017 were reviewed, and 1475 patients were initially included in the analysis; 38 were excluded owing to cisatracurium use, and 7 were excluded due to incomplete medical records. Finally, 1430 patients were included in the study; after propensity score matching, 444 were allocated in each group, namely, sugammadex and neostigmine